This case report describes one patient with ME/CFS who had abnormal hormone levels (low thyroid and adrenal hormones, but high cortisol) and brain imaging showing shrinkage of the brain's outer layer. When treated with a low dose of a medication called modafinil along with lifestyle changes, the patient's symptoms improved. The study highlights that ME/CFS can have measurable physical changes and that doctors need better tools to diagnose and treat this condition.
Why It Matters
This case provides rare objective evidence linking ME/CFS to measurable biological abnormalities—specifically neuroendocrine dysregulation and structural brain changes—which strengthens the argument that ME/CFS is an organic disease. Documenting treatment response offers clinical insights for practitioners managing similar patients, and the study underscores the need for systematic diagnostic protocols in primary care.
Observed Findings
Suppressed serum thyroid-stimulating hormone (TSH) and adrenocorticotropic hormone (ACTH) levels
24-hour urinary cortisol excretion approximately twice the upper limit of normal
Significant cortical atrophy on computed tomography imaging
Clinical symptom improvement following low-dose modafinil plus nonpharmacologic intervention
Five-year disease history with initially nonspecific symptom presentation preceding SEID diagnosis
Inferred Conclusions
SEID can be associated with measurable neuroendocrine dysfunction and structural neuroimaging abnormalities.
Low-dose modafinil, combined with nonpharmacologic approaches, may provide clinical benefit in selected patients.
Family practitioners require enhanced awareness and standardized diagnostic criteria to accurately recognize and manage SEID in clinical practice.
Remaining Questions
Are cortical atrophy and the observed neuroendocrine pattern common across ME/CFS populations, or were these findings unique to this patient?
What is the mechanism by which modafinil improved outcomes in this case, and which ME/CFS patients are most likely to benefit from this therapy?
What This Study Does Not Prove
As a single case report, this study does not prove that all ME/CFS patients have cortical atrophy, abnormal cortisol levels, or will respond to modafinil. The findings may not be representative of the broader ME/CFS population, and the improvement observed could be due to natural fluctuation, placebo effect, nonpharmacologic interventions, or a combination of factors rather than modafinil alone. Causality between these biological findings and disease pathophysiology cannot be established from one case.
Tags
Symptom:Fatigue
Biomarker:NeuroimagingBlood Biomarker
Method Flag:PEM Not DefinedNo ControlsSmall SampleExploratory Only